LONDON, January 14, 2015 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
http://investor-edge.com/register
CTI BioPharma Corp.'s stock surged 3.91%, to close the day at $2.39. The stock recorded a trading volume of 5.03 million shares, much above its three months average volume of 1.47 million shares. The company's shares oscillated between $2.35 and $2.55 during the session. Over the previous three trading sessions and over the past three months, CTI BioPharma Corp.'s shares have advanced 1.27% and 6.70%, respectively. However, the stock has fallen by 0.42% in the last one month. The company's stock is trading above its 50-day moving average of $2.30, while the 50-day moving average is below CTI BioPharma Corp.'s 200-day moving average of $2.63. Additionally, the stock has a Relative Strength Index (RSI) of 47.17. Sign up and read the free notes on CTIC at:
http://get.Investor-Edge.com/pdf/?c=CTI%20BioPharma&d=14-Jan-2015&s=CTIC
On Tuesday, shares in Keryx Biopharmaceuticals Inc. recorded a trading volume of 1.74 million shares, higher than its three months average volume of 1.30 million shares. The stock ended the day at $13.67, which was 4.41% below its previous day's closing of $14.30, and registered an intraday range of $13.50 and $14.49. Keryx Biopharmaceuticals Inc.'s shares have fallen by 4.87% in the previous three trading sessions and 5.72% in the last one month, while the stock has advanced 4.43% in the past one year. The company's stock is trading below its 50-day and 200-day moving averages of $15.14 and $14.98, respectively. Furthermore, shares of Keryx Biopharmaceuticals Inc. have an RSI of 48.35. The complimentary notes on KERX can be downloaded as in PDF format at:
http://get.Investor-Edge.com/pdf/?c=Keryx%20Biopharma&d=14-Jan-2015&s=KERX
Intrexon Corp.'s stock declined 3.83% to end Tuesday's session at $28.37. The stock recorded a trading volume of 0.58 million shares, below its three months average volume of 0.63 million shares. The company's shares fluctuated between $27.84 and $29.99 during the session. Intrexon Corp.'s shares have rallied 70.80% in the past three months. Further, the stock has advanced 1.29% in the previous three trading sessions and 5.04% over the last one month. The company's stock is trading above its 50-day and 200-day moving averages. Intrexon Corp.'s 50-day moving average of $25.39 is above its 200-day moving average of $22.08. Additionally, the stock has an RSI of 64.43. Register for free on Investor-Edge and access the latest research on XON at:
http://get.Investor-Edge.com/pdf/?c=Intrexon&d=14-Jan-2015&s=XON
On Tuesday, shares in Catalyst Pharmaceutical Partners Inc. fluctuated between $2.82 and $3.02 before ending the session 3.04% lower at $2.87. The stock reported a trading volume of 0.40 million shares, lower than its three months average volume of 0.51 million shares. Catalyst Pharmaceutical Partners Inc.'s stock has surged 4.74% in the previous three trading sessions, 15.26% in the last three months, and 38.65% in the past one year. The company's stock is trading above its 50-day and 200-day moving averages of $2.83 and $2.51, respectively. Moreover, shares of Catalyst Pharmaceutical Partners Inc. have an RSI of 55.11. The complete research on CPRX is available for free at:
http://get.Investor-Edge.com/pdf/?c=Catalyst%20Pharma%20Partners&d=14-Jan-2015&s=CPRX
iBio Inc.'s stock finished Tuesday's session 1.50% higher at $0.46. A total of 0.52 million shares were traded, which was much below its three months average volume of 6.12 million shares. The stock vacillated between $0.46 and $0.49 during the session. Over the previous three trading sessions and over the last one month, iBio Inc.'s shares have plummeted 9.80% and 33.33%, respectively. However, over the past one year, the stock has advanced 5.99%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $0.85 is greater than its 200-day moving average of $0.66. iBio Inc.'s stock has an RSI of 27.42. Free in depth research on IBIO is available at:
http://get.Investor-Edge.com/pdf/?c=iBio&d=14-Jan-2015&s=IBIO
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
